The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $31.48

Today's change+0.50 +1.60%
Updated March 23 2:42 PM EDT. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $31.48

Today's change+0.50 +1.60%
Updated March 23 2:42 PM EDT. Delayed by at least 15 minutes.

AstraZeneca PLC Hits New 100-day High

AstraZeneca PLC is up sharply today, rallying (U.S.)$0.50 or 1.60% to (U.S.)$31.48 and setting a new 100-day high. Over the last five days, shares have gained 3.13% and 15.21% year to date. Shares have underperformed the S&P 500 by 3.16% during the last year.

Key company metrics

  • Open(U.S.) $31.16
  • Previous close(U.S.) $30.98
  • High(U.S.) $31.60
  • Low(U.S.) $31.14
  • Bid / Ask(U.S.) $31.47 / (U.S.) $31.48
  • YTD % change+15.21%
  • Volume9,594,192
  • Average volume (10-day)4,535,192
  • Average volume (1-month)4,898,515
  • Average volume (3-month)6,987,007
  • 52-week range(U.S.) $25.55 to (U.S.) $35.04
  • Beta0.83
  • Trailing P/E22.77×
  • P/E 1 year forward16.96×
  • Forward PEG2.20×
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield4.45%
  • Trailing EPS(U.S.) $1.38
Updated March 23 2:42 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+14.81%

Based on its net profit margin of 14.81%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.69%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue5,5855,6995,6036,115
Total other revenue--------
Total revenue5,5855,6995,6036,115
Gross profit4,4684,8584,5605,120
Total cost of revenue1,1178411,043995
Total operating expense3,0524,6715,3005,077
Selling / general / administrative2,1331,9682,1912,203
Research & development1,4811,3371,3841,429
Depreciation / amortization298297309263
Interest expense (income), net operating--------
Unusual expense (income)-835335765263
Other operating expenses, total-1,142-107-392-76
Operating income2,5331,0283031,038
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax2,183676-30723
Income after tax1,817995-31625
Income tax, total366-319198
Net income1,8421,014-3646
Total adjustments to net income--------
Net income before extra. items1,8421,014-3646
Minority interest25192821
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,8421,014-3646
Inc. avail. to common incl. extra. items1,8421,014-3646
Diluted net income1,8421,014-3646
Dilution adjustment00--0
Diluted weighted average shares1,2661,2661,2651,265
Diluted EPS excluding extraordinary itemsvalue per share1.450.800.000.51
Dividends per sharevalue per share--0.000.900.00
Diluted normalized EPSvalue per share1.151.070.590.73